Education
About Us
Working with TipRanks
Follow Us
PBE - ETF AI Analysis
Top Page
Invesco Dynamic Biotechnology & Genome ETF (PBE)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains so far this year, reflecting positive momentum in the biotechnology sector.
Top Holdings with Strong Gains
Several top holdings, such as Ionis Pharmaceuticals and Royalty Pharma, have shown strong year-to-date performance, supporting the fund’s overall returns.
Focused Sector Exposure
The ETF’s concentration in the health care sector allows investors to benefit from growth in biotechnology and genome innovation.
Negative Factors
High Sector Concentration
Nearly all of the ETF’s exposure is in the health care sector, which increases vulnerability to industry-specific risks.
Underperforming Holdings
Some top holdings, like Illumina and Regeneron, have lagged in performance, potentially dragging down overall returns.
Limited Geographic Diversification
The ETF is heavily focused on U.S. companies, offering little exposure to international markets.
PBE vs. SPDR S&P 500 ETF (SPY)
AUM253.98M
RegionNorth America
Expense Ratio0.58%
Beta0.74
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield0.49%
Asset ClassEquity
Index TrackedDynamic Biotech & Genome Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,466
30 Day Avg. Volume5,182
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
97.54Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PBE Summary
The Invesco Dynamic Biotechnology & Genome ETF (PBE) is a fund that focuses on companies in the biotechnology and genomic research sector, which are part of the health care industry. It includes well-known companies like Vertex Pharmaceuticals and Gilead Sciences, both of which are leaders in developing innovative medical treatments. This ETF is ideal for investors who want to tap into the growth potential of cutting-edge health care solutions and scientific advancements. However, new investors should be aware that the ETF’s performance is closely tied to the biotechnology sector, which can be volatile and sensitive to changes in research outcomes or regulatory decisions.
How much will it cost me?The expense ratio for the Invesco Dynamic Biotechnology & Genome ETF (PBE) is 0.58%, which means you’ll pay $5.80 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on specialized biotechnology and genomic research companies that require more in-depth analysis and management.
What would affect this ETF?The Invesco Dynamic Biotechnology & Genome ETF (PBE) could benefit from advancements in biotechnology and genomic research, as well as increased demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or economic downturns that could impact funding for biotech companies. The ETF’s focus on U.S.-based firms and top holdings like Vertex Pharmaceuticals and Gilead Sciences highlights its reliance on the performance of leading biotech innovators.
PBE Top 10 Holdings
The Invesco Dynamic Biotechnology & Genome ETF (PBE) is heavily concentrated in the U.S. biotechnology sector, with names like Exact Sciences and Ionis Pharmaceuticals leading the charge thanks to strong revenue growth and bullish momentum. Exact Sciences, in particular, is rising on the back of strategic product launches, while Ionis benefits from pipeline advancements despite financial risks. On the flip side, Illumina is lagging slightly, grappling with cash flow challenges that temper its recovery. With a mix of established players like Regeneron and emerging innovators, this fund is a bet on the future of healthcare breakthroughs.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Illumina | 5.41% | $13.73M | $20.61B | -6.26% | 71 Outperform | |
| United Therapeutics | 5.23% | $13.28M | $21.27B | 36.53% | 79 Outperform | |
| Biogen | 4.97% | $12.63M | $25.54B | 16.04% | 74 Outperform | |
| Regeneron | 4.92% | $12.49M | $77.91B | 1.37% | 78 Outperform | |
| Gilead Sciences | 4.85% | $12.33M | $149.38B | 31.08% | 78 Outperform | |
| Amgen | 4.80% | $12.19M | $171.10B | 17.41% | 77 Outperform | |
| Alnylam Pharma | 4.62% | $11.74M | $52.52B | 61.97% | 60 Neutral | |
| Incyte | 4.53% | $11.52M | $18.73B | 39.18% | 81 Outperform | |
| MannKind | 3.19% | $8.10M | $1.82B | -9.17% | 64 Neutral | |
| ACADIA Pharmaceuticals | 3.13% | $7.95M | $4.59B | 57.30% | 75 Outperform |
PBE Technical Analysis
Positive
―
Price Trends
76.43
Positive
72.31
Positive
67.66
Positive
Market Momentum
1.23
Positive
57.48
Neutral
29.70
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 80.56, equal to the 50-day MA of 76.43, and equal to the 200-day MA of 67.66, indicating a neutral trend. The MACD of 1.23 indicates Positive momentum. The RSI at 57.48 is Neutral, neither overbought nor oversold. The STOCH value of 29.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBE.
PBE Peer Comparison
Comparison Results
Performance Comparison
PBE
Invesco Dynamic Biotechnology & Genome ETF
80.56
12.16
17.78%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents